RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene ...
RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), ("Opus Genetics” or the "Company”), a clinical-stage biopharmaceutical company developing gene ...
AI companies say state laws hinder development Trump says single rule will help US compete Bipartisan opposition is expected from the states Dec 8 (Reuters) - U.S. President Donald Trump said on ...
Part of the shutdown deal, the ban could kill the cannabis genetics market, with only big firms able to comply For the first time since 2018, the sale of cannabis seeds in the US will be restricted ...
A large international genome-wide association study identified five new genetic variants and 22 high-probability risk genes linked to irritable bowel syndrome (IBS), narrowing the biological pathways ...
RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited ...
(MENAFN- GlobeNewsWire - Nasdaq) RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback